Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06040242
Other study ID # EAP_2020
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date August 1, 2023
Est. completion date August 31, 2025

Study information

Verified date April 2024
Source Swiss Federal Institute of Technology
Contact Fernando G Beltrami, PhD
Phone +41446330472
Email fernando.beltrami@hest.ethz.ch
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Current guidelines advocate that ARVC patients, typically young and active individuals with a significant history of competitive endurance sports, cease endurance training in favour of activities with low cardiac burden such as bowling and golf. Empirically, it is often suggested that heart rate during exercise should not exceed 100-120 bpm in these patients, but these guidelines are arbitrary and not scientifically based. In practice, it is estimated that up to 50% of patients do not comply with these recommendations . Adequate quantification of the arrhythmogenic burden, defined as premature ventricular beats in proportion to all heart beats in each period of time, and cardiac load (defined as stroke volume for volume load and systolic blood pressure for pressure load) experienced by ARVC patients when performing different types of physical exercise would be a first step towards designing a safe and effective intervention so that these patients can profit from an active life style. This study therefore aims to quantify and describe the arrhythmogenic burden and cardiac load experienced by patients with ARVC while performing different physical exercise over a range of intensities - all strictly within the range currently recommended by different cardiological societies.


Description:

In this study, ARVC patients with different genotypes will perform a series of different physical activities, including treadmill walking, cycling at different intensities, biceps curls and loaded squats while undergoing extensive cardiovascular monitoring.


Recruitment information / eligibility

Status Recruiting
Enrollment 64
Est. completion date August 31, 2025
Est. primary completion date August 31, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Definitive ARVC diagnosis according to the modified 2010 ARVC Task Force Criteria - Pathogenic / likely pathogenic variant in one of the following desmosomal genes: plakophilin-2 (PKP-2), desmoglein-2 (DSG-2) or desmoplakin (DSP) or gene-elusive definite ARVC (i.e., genetic test performed but no pathogenic / likely pathogenic variant found) - Agreement with responsible primary cardiologist that study participation is not considered beyond acceptable levels of physical activity for this particular patient - No history of exercise-induced syncope in the 6 months prior to study participation - No history of sudden cardiac arrest in the 6 months prior to study participation - In patients who suffered from sudden cardiac arrest/arrhythmic syncope, only those having an implantable cardioverter-defibrillator (ICD) and being under beta-blockers/antiarrhythmic drugs are eligible for study inclusion - Informed Consent as documented by signature (Appendix Informed Consent Form) - Age: > 18 years - Body-Mass-Index (BMI): 18.5 - 29.9 kg?m-2 - Willing to adhere to the following study rules: - No intense exercise 48h prior to testing - No exercise 24h prior to testing - Sleep at least 7h the two nights before testing On test day - No caffeinated food or drink before testing on test day - No alcohol before testing on test day - Fully compliant with normal medication regimen including beta-blockers and antiarrhythmic medication Exclusion Criteria: - No genetic test history for ARVC variants - Heart failure with severely reduced left ventricular ejection fraction (LVEF <35%) - For women: Pregnancy, breastfeeding, or intention to become pregnant during the study. - Known or suspected non-compliance, drug, or alcohol abuse - Inability to follow the procedures of the study, e.g., due to language problems, psychological disorders, dementia, etc. of the participant - Previous enrolment into the current study

Study Design


Related Conditions & MeSH terms

  • Arrhythmogenic Right Ventricular Cardiomyopathy
  • Arrhythmogenic Right Ventricular Dysplasia
  • Cardiomyopathies

Intervention

Other:
Exercise
Participants will perform 3 min of the different activities, followed by a 10-min recovery window.

Locations

Country Name City State
Switzerland Exercise Physiology Lab, Institute of Human Movement Sciences and Sport, ETH Zurich Zurich ZH

Sponsors (2)

Lead Sponsor Collaborator
Swiss Federal Institute of Technology University of Zurich

Country where clinical trial is conducted

Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Primary count of premature ventricular beats during and after the activities count of premature ventricular beats during and after the activities measured during the 3 min of activity and the 10 min of recovery
Secondary cardiac load during different activities, as rate-pressure product product of heart rate and systolic blood pressure measured during the 3 min of activity
Secondary cardiac load during different activities, as cardiac output product of heart rate and stroke volume, in L/min measured during the 3 min of activity
Secondary cardiac load during different activities, as peak blood pressure systolic blood pressure, in mmHg measured during the 3 min of activity
See also
  Status Clinical Trial Phase
Completed NCT03177018 - DNA Analysis From Isolated Cardiomyocytes in the Molecular Diagnosis of Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia N/A
Recruiting NCT05799833 - Low QRS Voltages in Young Healthy Individuals and Athletes
Recruiting NCT03061994 - Metabolomic Study of All-age Cardiomyopathy N/A
Completed NCT00292032 - Registry of Unexplained Cardiac Arrest
Completed NCT04124237 - Long Term Monitoring for Risk of Sudden Death
Recruiting NCT06228924 - Open-label, Dose Escalation Study of Safety and Preliminary Efficacy of TN-401 in Adults With PKP2 Mutation-associated ARVC Phase 1
Enrolling by invitation NCT03527342 - Sahlgrenska Cardiomyopathy Project
Completed NCT03685149 - Pilot Randomized Trial With Flecainide in ARVC Patients Phase 2
Recruiting NCT03076580 - An Integrative-"Omics" Study of Cardiomyopathy Patients for Diagnosis and Prognosis in China
Completed NCT02302274 - Diagnostic Value and Safety of Flecainide Infusion Test in Brugada Syndrome
Recruiting NCT06311708 - Non-interventional Study of Seroprevalence of Pre-existing Antibodies Against Adenovirus-associated Virus Vector (AAV9) and the Progression of Disease in Patients With Plakophilin 2 (PKP2)-Associated Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)
Recruiting NCT03572569 - Risk Stratification in Children and Adolescents With Primary Cardiomyopathy
Completed NCT01804699 - National ARVC Data Registry and Bio Bank
Recruiting NCT05024708 - Athlete's Heart or Arrhythmogenic Right Ventricular Cardiomyopathy: Contribution of Exercise Cardiovascular Magnetic Resonance (CMR) N/A
Recruiting NCT03049254 - Mayo AVC Registry and Biobank
Recruiting NCT02989480 - PET-detected Myocardial Inflammation is a Characteristic of Cardiac Sarcoid But Not of ARVC
Completed NCT02291393 - The Role of High Density Surface ECG in the Diagnosis of Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) N/A
Recruiting NCT04265040 - DZHK TORCH-Plus is a Registry for Patients With Cardiomyopathies and Serves as Source for Cardiovascular Research Studies
Recruiting NCT02432092 - Pediatric Cardiomyopathy Mutation Analysis
Active, not recruiting NCT04895540 - South Asian Arrhythmogenic Cardiomyopathy Registry